← Human Trials & Peer-Reviewed Studies
Changes in N-terminal pro-B-type natriuretic peptide and incidence of diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA)
Plain-language guide to PMID 26047677 (2015): observational study of BNP (Nesiritide).
Key Facts
- PMID
- 26047677
- Journal
- Diabetes & metabolism
- Year
- 2015
- Study type
- Observational Study
- Authors
- Sanchez OA et al. (9 authors)
- DOI
- 10.1016/j.diabet.2015.04.005
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of BNP (Nesiritide), published as an observational study.
This study looked at whether the inverse association of circulating N-terminal pro-B-type natriuretic peptide (NT-proBNP) with incident diabetes is modified by changes in NT-proBNP (ΔNT-proBNP) levels.
A Poisson distribution was fitted to determine the incidence density of diabetes, adjusted for age, race, gender, educational attainment, antihypertensive medication, total intentional exercise and plasma IL-6 levels.
Who Took Part
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.
How the Study Was Run
Plasma NT-proBNP was assayed at baseline and 3.2 years later (visit 3) in the Multi-Ethnic Study of Atherosclerosis (MESA). ΔNT-proBNP was calculated as NT-proBNP visit3-NT-proBNP baseline.
In the primary analysis (n=3236 without diabetes up to visit 3, followed for a mean of 6.3 years), incidence density was regressed for the following categories of baseline NT-proBNP: (1)<54.4 pg/mL; (2) 54.4-85.9 pg/mL; and (3) 86-54.2 pg/mL.
This was crossed with categories of ΔNT-proBNP as medians (ranges): (1) -6.2 (-131-11.7) pg/mL; (2) 19.8 (11.8-30.1) pg/mL; (3) 44.0 (30.2-67.9) pg/mL; and (4) 111.2 (68.0-3749.9) pg/mL.
What Was Measured
Topics PubMed links to this paper include Asymptomatic Diseases, Atherosclerosis, Cohort Studies, Diabetes Mellitus, Type 2, Incidence, Interleukin-6 and Minnesota.
Author keywords: Change, MESA study, NT-proBNP and Natriuretic peptides.
What This Means in Plain Language
This is an observational study of BNP (Nesiritide).
Results are reported in around 3 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2015 (Diabetes & metabolism), a journal based in France.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.